Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumors.

Abstract

This study investigates the radiobiology of peptide receptor radionuclide therapy (PRRT) using clinically relevant cancer cell lines by developing a framework for realistic cellular dosimetry in 2- and 3-dimensional cluster-forming configurations. <b>Methods:</b> The radiobiologic responses of GOT1 and NCI-H69 tumor cell lines to PRRT and external beam radiotherapy (EBRT) were compared. Viability at 7 d and cell death at multiple time points were assessed. Image-based multicellular dosimetry models were developed to reflect in vitro exposure complexity and were compared with traditional approaches. <b>Results:</b> The PRRT absorbed dose in suspension was dominated by medium during incubation and by a cross-dose within small clusters after incubation. Our findings reveal that traditional dosimetry can underestimate absorbed doses by up to 90% in plated setups and overlooks dose heterogeneity, with initial dose rates varying by up to 2.3-fold based on cluster size and cell arrangement. The maximum relative biologic effectiveness of PRRT compared with EBRT for loss of viability at 7 d was 0.43 ± 0.07 for NCI-H69 cells and 0.22 ± 0.02 for GOT1 cells. NCI-H69 cells showed greater resistance to PRRT-induced cell death than to EBRT, whereas GOT1 cells exhibited similar cell death levels for both treatments, albeit with different dose-response dynamics. <b>Conclusion:</b> PRRT requires on average an absorbed dose 3 times higher than EBRT to achieve equivalent effects in vitro. Traditional dosimetry overestimates the relative biologic effectiveness by underestimating the absorbed dose.